In 2008, Brantley et al. suggested that STAT3 may be an attractive therapeutic target for glioblastoma because STAT3 is constitutively active as a consequence of phosphorylation at both Tyr705, as well as Ser727 [43]. The gene discussed is STAT3; the disease is glioblastoma.